Tag: Chemotherapy
Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancer
March 26, 2021 1:00 pmIxabepilone plus bevacizumab yielded responses in a third of patients.
By Ian Ingram
Combination treatment with a microtubule stabilizing agent plus bevacizumab (Avastin) proved active for patients with recurrent chemotherapy-resistant ovarian cancer, a randomized phase II trial found.
Median progression-free … Read more
Recent Chemotherapy or Immunotherapy for Gynecologic Cancer Does Not Raise Risk of Death Due to COVID-19
March 21, 2021 4:00 pmAlthough some studies show that patients with cancer have a greater risk of health complications from COVID-19, a new study has found that recent chemotherapy or immunotherapy for gynecologic cancer does not raise the risk of hospitalization or death due … Read more
Wee1 Inhibitor Gets Win in Tough-to-Treat Ovarian Cancer
January 25, 2021 5:00 pmBy Ian Ingram
Adding the Wee1 inhibitor adavosertib to gemcitabine reduced the risk of disease progression and death in women with recurrent, platinum-resistant or -refractory ovarian cancer, a randomized phase II trial showed.
For the primary endpoint of progression-free survival … Read more
New Combination Treatment for Recurrent Ovarian Cancer Shows Positive Outcomes
November 19, 2020 5:00 pmA team from Roswell Park Comprehensive Cancer Center has detailed striking findings on the effectiveness of a previously untried combination of old and new drugs as treatment for recurrent ovarian cancer.
In a new article in JAMA Oncology, the … Read more
Immunotherapy Falls Short Again in Ovarian Cancer
September 23, 2020 6:00 pmNo PFS benefit in advanced disease with addition of atezolizumab to chemo, bevacizumab.
By Charles Bankhead
An immunotherapy boost failed to improve outcomes in newly diagnosed advanced ovarian cancer compared with chemotherapy and bevacizumab (Avastin), a large international trial showed.… Read more
HIPEC With Cytoreductive Surgery Effective in Ovarian Cancer
August 25, 2020 5:00 pmBy Sarah Williams
For patients with stage III epithelial ovarian cancer, adding hyperthermic intraperitoneal chemotherapy (HIPEC) to primary cytoreductive surgery (PCS) increases survival compared with PCS alone, according to results of a retrospective study now published in JAMA Network Open… Read more
Chemotherapy, Surgery for Gynecologic Cancer Not Linked to Higher COVID-19 Mortality Risk
July 30, 2020 3:00 pmWomen who underwent chemotherapy or surgery for gynecologic cancer and also had COVID-19 infection did not appear at significantly increased risk for death due to the novel coronavirus, according to study findings published in Cancer.
However, recent immunotherapy use … Read more
Study Suggests QoL Assessments Do Not Support First-Line Combination Chemotherapy With Weekly Paclitaxel for Epithelial Ovarian Cancer
July 21, 2020 6:00 pmResults of quality of life (QoL) assessments from the randomized, phase 3 ICON8 study evaluating once-weekly vs thrice-weekly administration of paclitaxel in combination with carboplatin as first-line chemotherapy in patients with epithelial ovarian cancer do … Read more
New Standard in Recurrent, Platinum-Sensitive Ovarian Cancer
April 21, 2020 10:00 amBy Pam Harrison
Replacing gemcitabine (Gemzar) with pegylated liposomal doxorubicin in a standard platinum-based regimen improved survival in recurrent ovarian cancer, a phase III trial has shown.
In a cohort of nearly 700 women receiving carboplatin plus bevacizumab (Avastin), median … Read more
Olaparib Matches Chemotherapy Outcomes in Platinum-Sensitive Recurrent Ovarian Cancer
April 17, 2020 10:30 amBy Lisa Astor
Treatment with olaparib demonstrated similar outcomes to standard-of-care chemotherapy treatment in patients with BRCA wild-type, platinum-sensitive, recurrent epithelial ovarian cancer in the phase II CLIO study. As such, olaparib failed to demonstrate a significant improvement in survival … Read more
Olaparib/Bevacizumab as Frontline Maintenance Improves PFS in Ovarian Cancer, Regardless of Timing of Surgery, Disease Status
April 8, 2020 10:00 amBy Gina Columbus
The combination of olaparib (Lynparza) and bevacizumab (Avastin) was found to improve progression-free survival (PFS) outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous ovarian cancer, regardless of the … Read more
Analysis Pinpoints Veliparib Antitumor Activity in Ovarian Cancer
April 6, 2020 10:00 amBy Jason M. Broderick
Adding veliparib to frontline induction chemotherapy increased complete and CA-125 responses compared with chemotherapy alone in patients with high-grade serous ovarian cancer, according to an exploratory analysis of the phase III VELIA trial.1
The 3-arm … Read more
Water-Only Fasting May Reduce Chemo Modifications, Hospital Admissions
April 3, 2020 10:00 amBy Neil Osterweil
FROM SGO 2020
Patients with gynecologic malignancies who consumed only water for 24 hours before and 24 hours after each chemotherapy cycle had fewer dose delays and reductions compared with patients who didn’t fast, results of a
Advanced Ovarian Cancer: Survival & NAC Use Continue to Increase
April 2, 2020 11:00 amBy Pam Harrison
Uptake of neoadjuvant chemotherapy (NAC) for the treatment of advanced ovarian cancer has increased dramatically since 2006 in the United States, but importantly, the median survival has also continued to increase, new research shows.
These trends confirm … Read more
Navicixizumab Combo Shows Benefit in Heavily Pretreated Ovarian Cancer
April 2, 2020 10:45 amBy Jason M. Broderick
The anti-DLL4/VEGF bispecific antibody navicixizumab showed promising clinical activity when used in combination with paclitaxel in heavily pretreated patients with platinum-resistant ovarian cancer, according to findings from a phase Ib study.
The data build on positive … Read more
Phase 3 Trial Examining ICIs in Epithelial Ovarian Cancers Halted Due to Futility
March 31, 2020 11:00 amBy Susan Moench, PhD, PA-C
An interim analysis of results of the first phase 3 clinical trial evaluating an immune checkpoint inhibitor either in combination with or following platinum-based chemotherapy compared with chemotherapy alone in patients with previously untreated advanced … Read more
Immunotherapy With Neoadjuvant Chemotherapy Signals Efficacy in Advanced-Stage Ovarian Cancer
March 19, 2020 11:00 amBy Nichole Tucker
GEN-1 immunotherapy demonstrated dose-dependent efficacy results in newly diagnosed patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (EOC) when treated in combination with the standard of care, according to results from the OVATION 2 … Read more
Weekly Dose-Dense Chemo Not Recommended in First-Line Epithelial Ovarian Cancer Treatment
December 20, 2019 6:00 pmBy Matthew Fowler
Weekly dose-dense paclitaxel as a frontline treatment for patients with epithelial ovarian cancer was not found to significantly improve progression-free survival (PFS) compared to the standard 3-weekly chemotherapy, according to results from the ICON8 study published in … Read more
PARP Inhibitors: The Key to a Tx Paradigm Shift in Ovarian Cancer?
September 29, 2019 6:00 pmBy Ed Susman
PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines.
Patients with newly diagnosed advanced ovarian cancer who responded to first-line chemotherapy, then were treated with niraparib (Zejula), had a significantly reduced risk … Read more